Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Somatostatin analogs as radiodiagnostic tools.

× No keyword cloud information.

47 in total

1. [Diagnostic imaging of a TSH-producing pituitary adenoma associated with the "empty sella" by somatostatin and dopamine D2 receptor scintigraphy].

Authors: F Berger; G Meyer; M Weiss; T Pfluger; K Horn; K Tatsch; K Hahn
Journal: Nuklearmedizin Date: 2000 Impact factor: 1.379

2. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.

Authors: A Saveanu; G Gunz; H Dufour; P Caron; F Fina; L Ouafik; M D Culler; J P Moreau; A Enjalbert; P Jaquet
Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958

3. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy.

Authors: C C Chen; F S Czerwiec; P P Feuillan
Journal: J Nucl Med Date: 1998-02 Impact factor: 10.057

4. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.

Authors: P Meyer; N I Bohnen; A L Barkan; B Shapiro
Journal: Nuklearmedizin Date: 1999 Impact factor: 1.379

5. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].

Authors: R Görges; U Cordes; M Engelbach; K M Bartelt; G Haberern; O Hey; J Beyer; A Bockisch
Journal: Nuklearmedizin Date: 1997-06 Impact factor: 1.379

6. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.

Authors: G Boni; M Ferdeghini; C R Bellina; F Matteucci; E Castro Lopez; G Parenti; R Canapicchi; R Bianchi
Journal: Q J Nucl Med Date: 1995-12

7. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors: U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal: J Clin Endocrinol Metab Date: 1994-11 Impact factor: 5.958

8. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).

Authors: G Faglia; N Bazzoni; A Spada; M Arosio; B Ambrosi; F Spinelli; R Sara; C Bonino; F Lunghi
Journal: J Clin Endocrinol Metab Date: 1991-10 Impact factor: 5.958

9. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome.

Authors: Karel Pacak; Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Lynnette K Nieman
Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958

10. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

Authors: Y Greenman; S Melmed
Journal: J Clin Endocrinol Metab Date: 1994-09 Impact factor: 5.958

2 in total

Review 1. Somatostatin receptor imaging for neuroendocrine tumors.

Authors: Wouter W de Herder; Dik J Kwekkeboom; Richard A Feelders; Maarten O van Aken; Steven W J Lamberts; Aart-Jan van der Lely; Eric P Krenning
Journal: Pituitary Date: 2006 Impact factor: 4.107

2. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.

Authors: S Baldari; F Ferraù; C Alafaci; A Herberg; F Granata; V Militano; F M Salpietro; F Trimarchi; S Cannavò
Journal: Pituitary Date: 2012-12 Impact factor: 4.107

2 in total